Small Cap Feast

15th April 2024

Dish of the day
No Joiners today
Off the menu
No leavers today

Dish Of The Day:



Whats baking in the oven?

Potential Initial Public Offerings:

Reverse Takeovers:

Change of Market:

TheWorks (WRKS.L) a multi-channel value retailers of books, arts and crafts, stationery, toys and games, offering customers a differentiated proposition as a value alternative to full price specialist retailers. The Company is listed on the premium segment of the Main market of the London Stock Exchange. The Company has announced its intention to change to the AIM market on the 3 May 2024.

Banquet Buffet

Audioboom 260p £42.6m (BOOM.L)
The global podcast company announces its final audited results for the year ended 31 December 2023. Revenue decreased to $65m (2022: $74.9m). Adjusted EBITDA loss of $0.4m (2022: $3.6m profit), Average 2023 global monthly downloads increased 4% to $121.9m (2022: $117.1m). Furthermore, Cash balance of $3.7m (2022: $8.1m). The Company anticipates record revenue in 2024 and a return to adjusted EBITDA profitability.

Checkit 22p £23.8m (CKT.L)
The augmented workflow and smart sensor automation company for frontline workers announces a new product launch and contract wins in the UK. The Company announces the launch of a new product, Asset Intelligence. This product module applies advanced analytics and Machine Learning to IoT data which will help enhance customer sustainability, reduce costs, and improve revenue. Furthermore, The Company announces new contract wins from two existing customers worth a minimum of £417,000 in total lifetime revenue over their three year terms.

Eco Buildings 10.5p £8.1m (ECOB.L)
The modular housing company announces that Dr Etrur Albani, co-founder and non-executive board member, has agreed to assume a full-time role as the Group's Executive Vice Chairman. In his new role, Dr Albani will be responsible for managing existing client relationships as well as developing new contracts, working with CEO Sanjay Bowry in setting and maintaining the Company's strategy on how best to capture the rapidly growing demand for modular housing worldwide in general, and for the Group's innovative product offering in particular.

Engage XR Holdings 2p £10.5m (EXR.L)
The spatial computing and metaverse technology company announces its audited results for the 12 months ended 31 December 2023. Revenue decreased to £3.16m(2022: £3.33m), EBITDA loss reduced to £3.41m (2022: £4.95m), Cash balance of £6.74m (2022: £1.88m). Record revenue quarter in Q1 2024 of just over £1.7m contracted revenue booked in. Over 70% of this revenue is professional education.

European Green Transition 12.25p £17.7m (EGT.L)
The company developing green economy assets in Europe which aims to capitalise on the opportunity created by the green energy transition provides an update on certain developments relating to its principal asset, the Olserum Rare Earth Project in Sweden. The Company has concluded consultation with landowners and the Kalmar County Board and has been permitted to execute its work plan for drilling at the Olserum Rare Earth Project, which the Company expects to commence in H2 2024. The Company now has a valid work plan for an initial drilling program of up to 9,000m across 42 drill holes, with flexibility to alter the program within the approved working areas.

Faron Pharmaceuticals 127.5p £91.8m (FARN.L)
The clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments announces the appointment of Yrjö Wichmann as the Company's interim Chief Financial Officer, effective 15 April, 2024. Mr. Wichmann succeeds James O'Brien, who is leaving Faron to pursue another career opportunity.

Getech 8.75p £5.9m (GTC.L)
The locator of subsurface resources announces three separate contract wins related to the exploration of natural hydrogen. The first is a strategic joint venture exploration agreement with a new customer partner, while two additional contracts have been secured with existing exploration clients. The Company is at the forefront of this exciting new subsurface energy transition opportunity. Combined, the three transactions are expected to generate £390k of revenue over 3 years, with additional potential upside.

Fusion Antibodies 3.95p £3.8m (FAB.L)
The pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications announces that it has entered into a commercial contract to develop a bespoke OptiPhageTM library for a non-human antibody species with a global provider of antibodies for use in research and diagnostics. OptiPhageTM is Fusion's proprietary phage display platform based on the OptiMAL® library design but in a phage display format. It is anticipated that the Project will provide the Client with an alternative pathway to produce high quality antibodies, reducing its need to run animal-based antibody generation.

KRM22 27.5p £9.8m (KRM.L)
The technology and software investment company that focuses on risk management for capital markets announces the signing of a major customer contract for the Limits Manager product. The Company has completed the signing of a contract with a major Futures Commission Merchant, one of industry's top 15 largest FCMs. The three year contract, worth over £0.6m over the life of the contract, is for the Limits Manager product.

Savannah Resources 3.35p £61.2m (SAV.L)
The developer of the Barroso Lithium Project in Portugal, Europe's largest spodumene lithium deposit announces that, following the successful completion of his 6-month probationary period, Mr Emanuel Proença has been appointed as an Executive Director to the Company's Board of Directors with a commencement date of 15 April 2024, and has elected to take his fixed 2023 bonus in shares in lieu of cash.

15 April 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram